Inactive Instrument

Highlights Xynomic Pharmaceuticals Holdings, Inc. Other OTC

Equities

XYN

US98421X1028

Highlights

Unlock all the news: Be the first to know and act before the market!

BROOKLINE CAPITAL ACQUISITION CORP. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23/22/23	AQ
BROOKLINE CAPITAL ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	08/22/08	AQ
Apexigen and Brookline Capital Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Immuno-oncology Company	18/22/18	AQ
BROOKLINE CAPITAL ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	16/21/16	AQ
BROOKLINE CAPITAL ACQUISITION CORP. Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K/A)	24/21/24	AQ
BROOKLINE CAPITAL ACQUISITION CORP. : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	24/21/24	AQ
Xu-Nuo Pharma, Inc. acquired the remaining 2% stake in Xynomic Pharmaceuticals Holdings, Inc..	17/21/17	CI
BROOKLINE CAPITAL ACQUISITION CORP. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	05/21/05	AQ
Brookline Capital Acquisition Corp. Completes Closing of $57,500,000 Initial Public Offering	03/21/03	GL
Brookline Capital Acquisition Corp. Announces Pricing of $50,000,000 Initial Public Offering	29/21/29	GL
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	01/20/01	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	15/19/15	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives Fast-Track Designation from the US FDA for Abexinostat as 4L Therapy Treating Follicular Lymphoma	23/19/23	CI
Xynomic Pharma Doses First Chinese Patient in Pivotal Phase 3 Kidney Cancer Trial	14/19/14	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Encouraging Interim Data from Phase 1b Study of Abexinostat Combined with Keytruda in Multiple Solid Tumors	30/19/30	CI
Xynomic Research Institute Has Successfully Designed a Series of Potent RET Kinase Inhibitors	17/19/17	CI
Xynomic Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	16/19/16	CI
Xynomic Pharmaceuticals Holdings, Inc. Approves Application to Conduct Pivotal Phase 3 Trial Using Abexinostat	08/19/08	CI
Xynomic Pharmaceuticals Holdings, Inc. Files Fast-Track Designation Application for Follicular Lymphoma Treatment with the U.S. FDA	01/19/01	CI
Xynomic Pharmaceuticals Holdings, Inc. Receives China Approval to Start 2 Pivotal Lymphoma Clinical Trials	30/19/30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Xynomic Pharmaceuticals Holdings, Inc. Other OTC

Equities

XYN

US98421X1028

Highlights

Filters